Special Issue "Alzheimer's Disease: Molecular Mechanisms and Novel Treatment Strategies"
Deadline for manuscript submissions: 25 February 2024 | Viewed by 10122
2. Networking Research Center on Neurodegenerative Diseases (CIBERNED), 29010 Malaga, Spain
3. Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX 77030, USA
Interests: Alzheimer's disease; neurodegeneratrive diseases; amyloid beta; tau; neuroinflammation; risk factors; transgenic animals; preclinical trials
Interests: biomarkers; dementia; neurodegeneration; Tau; amyloid
Interests: nanotechnology and interfacial phenomena; effects of fluorinated systems and peptides on the aggregation of amyloid beta peptides; conformational studies of protein and peptide self-organized systems and polymer surfaces; design and production of inorganic and polymeric nanosystems for pharmaceutical and food applications
Special Issues, Collections and Topics in MDPI journals
Special Issue in Pharmaceutics: Lipid Nanoparticles in the Treatment of Neurological and Other Aging Related Disorders
Special Issue in Polymers: Polymeric Nanoparticles for Biomedical Applications
Special Issue in Pharmaceutics: Alzheimer's Disease: An Update on Novel Therapeutics
Alzheimer's disease (AD) is the most common form of dementia that accounts for around 50 million cases worldwide. Increasing life expectancy will triple this number by 2050. As long as we remain unable to reverse or prevent AD, its clinical, social, and economic burden will steadily increase hopelessly. The majority of AD cases are sporadic, indicating that the molecular mechanisms that trigger the late onset of the disease are still unknown. Currently, there is no definitive cure for AD, and current clinical interventions help to palliate some clinical symptoms. Prevention and modification of potential risk factors may reduce the probability of developing this type of dementia, but new and more effective therapeutic strategies are needed to prevent, slow down, or even halt the progression of the disease. This Special Issue aims to shed light on the recently described molecular mechanisms that are involved in Alzheimer's pathology, as well as collecting the latest advances in therapeutic interventions to combat this devastating condition.
Dr. Ines Moreno-Gonzalez
Dr. Claudia Duran-Aniotz
Prof. Dr. Joana A. Loureiro
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Alzheimer's disease
- risk factors